ATE352619T1 - Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten - Google Patents

Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten

Info

Publication number
ATE352619T1
ATE352619T1 AT99904660T AT99904660T ATE352619T1 AT E352619 T1 ATE352619 T1 AT E352619T1 AT 99904660 T AT99904660 T AT 99904660T AT 99904660 T AT99904660 T AT 99904660T AT E352619 T1 ATE352619 T1 AT E352619T1
Authority
AT
Austria
Prior art keywords
vertebrates
immunological compositions
modulating myostatin
myostatin
modulating
Prior art date
Application number
AT99904660T
Other languages
English (en)
Inventor
Christopher A Barker
Mohamad Morsey
Original Assignee
Metamorphix International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metamorphix International Inc filed Critical Metamorphix International Inc
Application granted granted Critical
Publication of ATE352619T1 publication Critical patent/ATE352619T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99904660T 1998-02-19 1999-02-19 Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten ATE352619T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7521398P 1998-02-19 1998-02-19

Publications (1)

Publication Number Publication Date
ATE352619T1 true ATE352619T1 (de) 2007-02-15

Family

ID=22124285

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99904660T ATE352619T1 (de) 1998-02-19 1999-02-19 Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten
AT06026306T ATE419353T1 (de) 1998-02-19 1999-02-19 Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06026306T ATE419353T1 (de) 1998-02-19 1999-02-19 Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten

Country Status (18)

Country Link
US (2) US6369201B1 (de)
EP (3) EP1770162B1 (de)
JP (1) JP2002504326A (de)
KR (1) KR20010041111A (de)
AR (1) AR019818A1 (de)
AT (2) ATE352619T1 (de)
AU (1) AU765014B2 (de)
BR (1) BR9907995A (de)
CA (2) CA2687533C (de)
CY (2) CY1108074T1 (de)
DE (2) DE69934970T2 (de)
DK (2) DK1770162T3 (de)
ES (3) ES2318654T3 (de)
IL (1) IL137831A0 (de)
NZ (1) NZ506911A (de)
PT (2) PT1770162E (de)
WO (1) WO1999042573A1 (de)
ZA (1) ZA991369B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US7566768B1 (en) * 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
WO2000043781A2 (en) * 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
KR100750695B1 (ko) * 1999-07-20 2007-08-22 파멕사 에이/에스 Gdf-8 활성을 하향-조절하는 방법
US6617440B1 (en) 1999-07-30 2003-09-09 Pfizer, Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
EP1593689A3 (de) * 2000-01-18 2006-04-05 Ovita Limited Myostatin und dessen Mimetika
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7192717B2 (en) * 2002-02-21 2007-03-20 Wyeth GASP1: a follistatin domain containing protein
JP4429728B2 (ja) * 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン(follistatin)ドメイン含有タンパク質
EP2192129A1 (de) * 2002-09-16 2010-06-02 Johns Hopkins University Metalloproteaseaktivierung von Myostatin sowie Verfahren zur Modulation der Myostatinaktivität
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
PT1581649E (pt) * 2002-12-20 2011-04-13 Amgen Inc Agentes de ligação que inibem a miostatina
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
AU2004312411B8 (en) * 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
MX2007000976A (es) * 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
WO2006036074A1 (en) * 2004-09-30 2006-04-06 Orico Limited Myostatin isoform
CA2594276A1 (en) * 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1864139A2 (de) * 2005-03-23 2007-12-12 Wyeth Nachweis einer immunreaktion auf gdf-8-modulierende wirkstoffe
JP2009518422A (ja) * 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
AU2007279456A1 (en) 2006-08-03 2008-02-07 Myostin Therapeutics Pty Ltd Myostatin antagonists
RS52787B (en) 2006-09-05 2013-10-31 Eli Lilly And Company MYSTATIN ANTIBODIES
MX2009012558A (es) 2007-08-03 2010-04-21 Biomarin Iga Ltd Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
CN104391628B (zh) * 2014-04-02 2018-02-23 贵阳朗玛信息技术股份有限公司 进程切换方法及装置
EP2960653A1 (de) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnosekit und Verfahren zur Identifizierung der Manipulation der Muskelmasse bei einem Haustier
US20220143136A1 (en) 2018-12-21 2022-05-12 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US20220135637A1 (en) 2019-03-01 2022-05-05 Knc Laboratories Co., Ltd. Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1605763A (en) 1926-11-02 Garment retainer
US2754818A (en) 1950-06-24 1956-07-17 Scherer Corp R P Hypo jet injector
US3330276A (en) 1963-10-07 1967-07-11 Scherer Corp R P Hypodermic jet injector
US3788315A (en) 1971-04-20 1974-01-29 S Laurens Disposable cutaneous transjector
US3853125A (en) 1971-10-05 1974-12-10 W Clark Disposable needleless injector
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
JPS5873993U (ja) 1981-11-12 1983-05-19 三菱電機株式会社 2気筒回転式圧縮機
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
EP0138854B1 (de) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigen aktive aminosäuresequenzen
US4518385A (en) 1983-06-13 1985-05-21 Preci-Tech Ltd. Disposable syringe for needleless injector
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5062830A (en) 1990-04-04 1991-11-05 Derata Corporation Dry disposable nozzle assembly for medical jet injector
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
DE69534468T2 (de) 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine Wachstums-differenzierungsfaktor-11
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
AU756620B2 (en) 1997-07-14 2003-01-16 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
AU1390999A (en) 1997-11-10 1999-05-31 Johns Hopkins University School Of Medicine, The Methods for detection of mutations in myostatin variants
CA2319703C (en) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
KR100750695B1 (ko) 1999-07-20 2007-08-22 파멕사 에이/에스 Gdf-8 활성을 하향-조절하는 방법

Also Published As

Publication number Publication date
EP1056845A1 (de) 2000-12-06
EP1770162A1 (de) 2007-04-04
EP1056845B1 (de) 2007-01-24
ATE419353T1 (de) 2009-01-15
AU2507399A (en) 1999-09-06
CA2323607C (en) 2009-12-22
PT1056845E (pt) 2007-04-30
ES2527410T3 (es) 2015-01-23
EP2018871A1 (de) 2009-01-28
DE69934970D1 (de) 2007-03-15
DE69934970T2 (de) 2007-10-25
AU765014B2 (en) 2003-09-04
ZA991369B (en) 1999-08-20
JP2002504326A (ja) 2002-02-12
CY1108889T1 (el) 2014-07-02
AR019818A1 (es) 2002-03-20
NZ506911A (en) 2003-09-26
IL137831A0 (en) 2001-10-31
EP2018871B1 (de) 2014-10-08
US6369201B1 (en) 2002-04-09
DK1770162T3 (da) 2009-04-14
BR9907995A (pt) 2001-05-15
WO1999042573A1 (en) 1999-08-26
EP1770162B1 (de) 2008-12-31
CY1108074T1 (el) 2014-02-12
US20030065137A1 (en) 2003-04-03
ES2280115T3 (es) 2007-09-01
KR20010041111A (ko) 2001-05-15
ES2318654T3 (es) 2009-05-01
DE69940230D1 (de) 2009-02-12
DK1056845T3 (da) 2007-05-29
CA2323607A1 (en) 1999-08-26
CA2687533C (en) 2016-02-02
PT1770162E (pt) 2009-03-24
CA2687533A1 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
DE69934970D1 (de) Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten
DE69819033D1 (de) Zusammensetzungen zum kleben von fluorkunststoffen
ID28965A (id) Azabisikloalkana sebagai modulator ccr5
DE60041430D1 (de) Zusammensetzung zur Entfernung von Photoresist
ID26549A (id) Komposisi-komposisi epotilon
ATE367793T1 (de) Schweisshemmende zusammensetzungen
DE69734090D1 (de) Web-Seiten Schnittstelle zur Angabe von Telefonie-Spezifikationen
ID26186A (id) Komposisi sampo
ID28694A (id) Komposisi sampo
ATE351896T1 (de) Brennstoffzusammensetzung
DE69919953D1 (de) Funktionelle zusammensetzungen
DE69903545D1 (de) Ölzusammensetzungen
DE69927758D1 (de) Imidosilan-Zusammensetzungen
DE69908507D1 (de) Zusammensetzung zur Bekämpfung von schädlichen Arthropoden
DE59911148D1 (de) Propoxilat enthaltende kraftstoffzusammensetzungen
DE69928862D1 (de) Zusammensetzung
DE69936208D1 (de) Modifiziermittel enthaltende zusammensetzung
DE69719442D1 (de) Frisierschaum-Zusammensetzungen
ID27889A (id) Komposisi-komposisi kopolimer polisiklik
DE69938619D1 (de) Weisse Tonerzusammensetzung
DE69718797D1 (de) Bituminöse zusammensetzung
DE69524995T2 (de) Schaltung zur Modulation der Abtastgeschwindigkeit
DE69804573T2 (de) Organopolysiloxan-Zusammensetzungen
DE69712523D1 (de) Flüssige kohlenwasserstoffzusammensetzungen
DE69901370D1 (de) Teilchenförmige Zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1056845

Country of ref document: EP